Northwest Biotherapeutics, Inc. (NWBO)

Market Cap	325.23M -6.9%
Revenue (ttm)	937.00K -41.3%
Net Income	-91.22M
EPS	-0.07
Shares Out	1.62B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,064,879
Average Volume	2,173,060
Open	0.2029
Previous Close	0.2000
Day's Range	0.2001 - 0.2116
52-Week Range	0.1772 - 0.4788
Beta	-0.77
RSI	38.31
Earnings Date	Apr 14, 2026

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 25
• Stock Exchange: OTCMKTS
• Ticker Symbol: NWBO

Financial Performance

In 2024, Northwest Biotherapeutics's revenue was $1.38 million, a decrease of -28.47% compared to the previous year's $1.93 million. Losses were -$85.19 million, 32.3% more than in 2023.